[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628520":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":26,"locations":26,"responsibleParty":35,"collaborators":37,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":26,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":26,"enrollmentInfo":50,"targetDuration":26,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":59,"overallStatus":67,"whyStopped":26,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":26},{"fullName":5,"class":6},"Medical University of South Carolina","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental Half of the Body","EXPERIMENTAL","Participants will apply the investigational topical medication to one half of the body that they choose",[13],"Drug: Topical Minocycline Foam FXFM244",{"label":15,"type":16,"description":17,"interventionNames":18},"Control Half of the Body","PLACEBO_COMPARATOR","Participants apply the control topical emollient without active ingredient to the contralateral half of the body",[19],"Other: Control",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Topical Minocycline Foam FXFM244","Topical minocycline foam that will be applied to half of the subject's body that will be chosen by the subject.",[9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Control","Control topical emollient that will be applied to the contralateral half of the body.",[15],[32],{"name":33,"affiliation":5,"role":34},"Lara Wine Lee, MD","PRINCIPAL_INVESTIGATOR",{"type":36,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[38],{"name":39,"class":40},"Journey Medical Corporation","INDUSTRY","100628520","early-phase-1-topical-minocycline-for-carp-100628520",false,"NCT07462702","Topical Minocycline for CARP","Topical Minocycline Foam for Treatment of Confluent and Reticulated Papillomatosis (CARP)","Inclusion Criteria:\n\n* Age ≥ 9 years\n* Clinical diagnosis of CARP\n\nExclusion Criteria:\n\n* Current or recent (within 6 months) use of oral minocycline\n* Pregnancy or breastfeeding\n* History of intracranial hypertension, autoimmune disorder, liver\u002Fkidney disease\n* Immunocompromised status\n* Hypersensitivity to tetracyclines\n* Unstable medical condition\n* Inability or unwillingness to provide informed consent","ALL","9 Years",{"count":51,"type":52},35,"ESTIMATED","INTERVENTIONAL",[55],"EARLY_PHASE1","This proof-of-concept trial evaluates the efficacy, safety, and patient satisfaction of topical minocycline foam (AMZEEQ®) in patients aged 9 and older with confluent and reticulated papillomatosis (CARP). Participants will apply AMZEEQ® to one side of the body and a topical emollient to the other for 5 weeks, followed by an optional extension period. The study aims to assess whether topical minocycline is a well-tolerated and effective alternative to oral antibiotics.",[58],"Confluent and Reticulated Papillomatosis (CARP)",[60,61,62,63,64,65,66],"Topical Minocycline","Confluent and reticulated papillomatosis (CARP)","CARP","Confluent and reticulated papillomatosis","Minocycline","Tetracycline","Pruritus","NOT_YET_RECRUITING","2026-07-20",{"date":70,"type":71},"2026-07-21","ACTUAL",{"date":73,"type":52},"2026-09-15",{"date":75,"type":52},"2028-02",{"name":5,"class":6}]